ANTI-BAG3 ANTIBODIES FOR THERAPEUTIC USE
The present invention relates to the use of BAGS antibodies as a medicament, in particular for use in the treatment of pancreatic tumours or other pathologies of an immune, inflammatory, neoplastic and/or degenerative nature.
1 - 16 . (canceled)
17 . A method for treating neoplastic diseases, inflammatory diseases, immune diseases and/or degenerative diseases, comprising administering an anti-BAG3 antibody to a subject in need thereof, wherein BAG3 protein is soluble.
18 . The method according to claim 17 , wherein said neoplastic disease is pancreatic tumor.
19 . The method according to claim 17 , wherein said neoplastic disease is bladder tumor.
20 . The method according to claim 17 , wherein said anti-BAG3 antibody is a polyclonal antibody.
21 . The method according to claim 17 , wherein said anti-BAG3 antibody is a monoclonal antibody.
22 . The method according to claim 21 , wherein said monoclonal antibody is a murine antibody, a humanized antibody, a chimeric antibody, a recombinant antibody, a conjugated antibody, an scFv fragment, a Fab fragment or a F(ab′)2 fragment.
23 . The method according to claim 22 , wherein said scFv fragment is diabody, triabody or tetrabody.
24 . The method according to claim 22 , wherein said monoclonal antibody is produced by at least one of the nine mother clones selected from the group consisting of: AC-1, AC-2, AC-3, AC-4, AC-5, AC-6, AC-7, AC-8 and AC-9.
25 . The method according to claim 24 , wherein said monoclonal antibody is produced by at least one of the five mother clones selected from the group consisting of: AC-1, AC-2, AC-3, AC-4, and AC-5.
26 . The method according to claim 22 , wherein said monoclonal antibody is produced by at least one of the following clones: AC-rb1, AC-rb2, AC-rb3, or AC-rb4, and by at least one of the following subclones: AC-rb1a, AC-rb1b, AC-rb2a, AC-rb2b, AC-rb3a, AC-rb3b, AC-rb4a, or AC-rb4b.
27 . A pharmaceutical composition comprising at least one anti-BAG3 antibody and at least one pharmaceutically acceptable excipient, wherein the BAG3 protein is soluble.
28 . The pharmaceutical composition according to claim 27 , wherein said anti-BAG3 antibody is a monoclonal antibody produced by at least one of the nine mother clones selected from the group consisting of: AC-1, AC-2, AC-3, AC-4, AC-5, AC-6, AC-7, AC-8 and AC-9.
29 . The pharmaceutical composition according to claim 27 , wherein said anti-BAG3 antibody is a monoclonal antibody produced by at least one of the five mother clones selected from the group consisting of: AC-1, AC-2, AC-3, AC-4, and AC-5.
30 . The pharmaceutical composition according to claim 27 , wherein said composition is formulated in a form suitable for oral administration, parenteral administration, or topical administration.
31 . The pharmaceutical composition according to claim 30 , wherein said form suitable for oral administration is selected from the group consisting of tablets, capsules, solutions, suspensions, granules, and oily capsules.
32 . The pharmaceutical composition according to claim 30 , wherein said parenteral administration is intramuscular, intravenous, intradermal, subcutaneous, intraperitoneal, intranodal, or intrasplenic administration.
33 . The pharmaceutical composition according to claim 30 , wherein said form suitable for topical administration is cream, salve, ointment, or gel.
34 . The pharmaceutical composition according to claim 30 , wherein said form suitable for parenteral administration is an aqueous buffer solution or an oily suspension.